The clinical and prognostic significance of CMTM6/PD-L1 in oncology

The recent discovery of CMTM6 and to a lesser extent CMTM4, two members of the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family, as master positive regulators of PD-L1 expression, the primary ligand of programmed cell death 1 (PD-1), on tumor and immune cells has opene...

Full description

Saved in:
Bibliographic Details
Published inClinical & translational oncology Vol. 24; no. 8; pp. 1478 - 1491
Main Authors Yaseen, Mahmoud Mohammad, Abuharfeil, Nizar Mohammad, Darmani, Homa
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.08.2022
Subjects
Medicine
Medicine & Public Health
Oncology
Review Article
Prognostic value
Tumor-infiltrating immune cells
Overall survival
Bioinformatics
Gene databases
Online AccessGet full text

Cover

More Information
Summary:The recent discovery of CMTM6 and to a lesser extent CMTM4, two members of the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family, as master positive regulators of PD-L1 expression, the primary ligand of programmed cell death 1 (PD-1), on tumor and immune cells has opened new horizons for investigating the role of CMTM6/CMTM4 in different aspects of oncology including their clinical and prognostic values in different cancer types. The absence of a specific review article addressing the available results about the clinical and prognostic roles of CMTM6 alone and/or in combination with PD-L1 in cancer has encouraged us to write this paper.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1699-3055
1699-3055
DOI:10.1007/s12094-022-02811-0